Immuno-Oncology | Specialty

Pembrolizumab Plus Chemo Does Not Significantly Improve Survival in TKI-resistant, EGFR+ NSCLC

June 6th 2023

The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy resulted in a numerical, but not statistically significant, improvement in progression-free survival or overall survival vs chemotherapy plus placebo in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer.

Cabozantinib/Atezolizumab Combo Misses PFS, OS End Points in ICI-Treated, Advanced RCC

June 5th 2023

The addition of atezolizumab to cabozantinib did not improve progression-free survival or overall survival vs cabozantinib alone in patients with advanced renal cell carcinoma who previously received treatment with an immune checkpoint inhibitor, missing the primary end points of the phase 3 CONTACT-03 trial.

Talquetamab Plus Daratumumab Produces Potent Responses in R/R Multiple Myeloma

June 4th 2023

Talquetamab plus daratumumab displayed high response rates regardless of 0.4 mg/kg or 0.8 mg/kg dosing in combination with daratumumab in patients with heavily pretreated relapsed/refractory multiple myeloma, irrespective of prior treatment with CD38-directed therapy and T-cell redirection therapy.

Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC

June 3rd 2023

The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.

EMA Recommends Approval of Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC

May 26th 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab as neoadjuvant therapy in combination with platinum-based chemotherapy for patients with resectable non–small cell lung cancer at high risk of recurrence and tumor cell PD-L1 expression of at least 1%.

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

May 23rd 2023

The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.

GEN-002 Plus Avelumab Shows Promise as Third-line Option in PD-L1+ Gastric Cancer

May 22nd 2023

The combination of GEN-002 and avelumab elicited responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from an interim analysis of an ongoing phase 2 trial.

CG0070 Plus Pembrolizumab Produces Durable Responses in BCG-Unresponsive NMIBC

May 18th 2023

Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.

Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer

May 10th 2023

John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.

Neoadjuvant Atezolizumab Followed by Adjuvant Atezolizumab May Benefit Select Patients With Early-stage NSCLC

May 3rd 2023

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

First-line Cemiplimab Plus Chemo Wins Approval in Canada for Advanced NSCLC

May 2nd 2023

Health Canada has approved the combination of cemiplimab and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer without EGFR, ALK, or ROS1 aberrations who are not candidates for definitive chemoradiation.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

May 1st 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

Cabozantinib/Atezolizumab Combo Provides Durable Benefit in Non–clear Cell RCC, Across Histological Subtypes

April 27th 2023

Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.

Nivolumab/Ipilimumab Prolongs Survival in Metastatic Clear Cell RCC Subsets

April 27th 2023

Treatment with nivolumab plus ipilimumab and a subsequent TKI was effective in patients with metastatic clear cell renal cell carcinoma.

EMA Validates Type II Variation Application for Dostarlimab/Chemo for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

April 25th 2023

The European Medicines Agency has validated a type II variation for potential approval of dostarlimab in combination with carboplatin and paclitaxel for the treatment of patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Sugemalimab Monotherapy Has Clinical Benefit in NK/T-Cell Lymphoma

April 24th 2023

The PD-L1 inhibitor sugemalimab produced durable responses with a tolerable safety profile in patients with relapsed/refractory natural killer/T-cell lymphoma, according to findings from a preplanned primary analysis of the multicenter, single-arm, phase 2 GEMSTONE-201 trial.

PARP Inhibitors, ADCs, and Immunotherapy Approaches Advance the Treatment Paradigm in Gynecologic Oncology

April 24th 2023

Joshua G. Cohen, MD, FACOG, FACS, expands on the role of PARP inhibitors in the recurrent and up-front settings in ovarian cancer, and the clinical significance of the RUBY and NY-GY018 trials in endometrial cancer.

Long-term Outcomes From JAVELIN Bladder 100 Solidify Maintenance Avelumab as SOC in Metastatic Urothelial Carcinoma

April 22nd 2023

A long-term post-hoc analysis from the JAVELIN Bladder 100 trial demonstrated that first-line maintenance avelumab elicited similar overall survival and progression-free survival benefits vs best supportive care alone in patients with advanced urothelial carcinoma.

Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence

April 19th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

Perioperative Durvalumab Plus Neoadjuvant Chemo Improves pCR, EFS in Resectable NSCLC

April 16th 2023

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.